ESR1 and breast cancer: AMD3100 also reduced the molecules that we demonstrated upregulation in the trastuzumab-resistant breast cancer cells comparing their parental cells, including ERα, Notch3, IGFBP2, and dual specificity phosphatase 4 (DUSP4), which contribute to cancer formation and progression or resistance to anti-HER2 therapy or chemotherapy [45–47].